Answers are grounded in this paper and cite their sources.
Every year, 10% to 20% of patients with idiopathic pulmonary fibrosis have an acute exacerbation (AE-IPF).1 American Thoracic Society1 guidelines make a weak recommendation for corticosteroid use to treat AE-IPF; however, the risks, benefits, and optimal dose of corticosteroids in AE-IPF remain unclear. Corticosteroid use is common,2 but dosing for AE-IPF can vary widely, from doses similar to COPD exacerbations (eg, 60-120 mg methylprednisolone) to higher pulse doses (eg, 500-1,000 mg methylprednisolone), with varying pharmacokinetic effects.
No takes yet. Share an insight, caveat, or question.
Shankar et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: